In a previous work, our group has demonstrated the effectiveness of MET inhibition, by both tivantinib (ARQ 197) and a specific short hairpin RNA (shRNA) against MET, in delaying the onset of experimental breast cancer-derived bone metastases. The gene discussed is MET; the disease is breast carcinoma.